Avacta says salivary gland cancer drug shrinks tumour
(Alliance News) - Avacta Group PLC on Wednesday said new data demonstrated that its drug caused "robust and meaningful" tumour shrinkage in patients with salivary gland cancer. Read More
| Price | 55.00p on 16-01-2026 at 19:40:05 |
|---|---|
| Change | -1.60p -2.83% |
| Buy | 56.00p |
| Sell | 54.00p |
| Last Trade: | Unknown 50,000.00 at 55.00p |
| Day's Volume: | 1,259,093 |
| Last Close: | 55.00p |
| Open: | 56.00p |
| ISIN: | GB00BYYW9G87 |
| Day's Range | 55.00p - 56.00p |
| 52wk Range: | 27.25p - 83.20p |
| Market Capitalisation: | £238.51m |
| VWAP: | 55.4424p |
| Shares in Issue: | 433.66m |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Avacta Group (AVCT) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Unknown* | 50,000 | 55.00p | OTC Trade |
17:07:26 - 16-Jan-26 |
| Unknown* | 25,000 | 55.00p | Uncrossing Trade |
16:35:13 - 16-Jan-26 |
| Buy* | 574 | 55.00p | Ordinary |
16:28:20 - 16-Jan-26 |
| Buy* | 8,834 | 55.00p | Ordinary |
16:23:58 - 16-Jan-26 |
| Buy* | 25,000 | 56.00p | Ordinary |
16:20:45 - 16-Jan-26 |
| Buy* | 50,000 | 55.675p | Ordinary |
16:13:34 - 16-Jan-26 |
| Sell* | 8,000 | 54.888p | Ordinary |
16:12:06 - 16-Jan-26 |
| Buy* | 1,793 | 55.75p | Ordinary |
16:10:36 - 16-Jan-26 |
| Buy* | 60,000 | 55.70p | Ordinary |
16:10:28 - 16-Jan-26 |
| Buy* | 9,028 | 55.38p | Ordinary |
16:09:06 - 16-Jan-26 |
Avacta Group (AVCT) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 18th Dec 2025 7:00 am | RNS-R | Avacta reports new AVA6103 pharmacology data |
| 17th Dec 2025 7:00 am | RNS | Faridoxorubicin Phase 1b SGC data |
| 8th Dec 2025 7:00 am | RNS | Preliminary Data in Faridoxorubicin Phase 1b Trial |
| 3rd Nov 2025 8:24 am | RNS | Completion of Placing and TVR |
| 27th Oct 2025 5:39 pm | RNS | Block Listing Six Monthly Return |
| 27th Oct 2025 7:00 am | RNS | Avacta presents preclinical data at AACR-NCI-EORTC |
| 23rd Oct 2025 5:00 pm | RNS-R | Notice of Investor Presentation |
| 20th Oct 2025 7:01 am | RNS | Equity fundraise of £16 million |
| 20th Oct 2025 7:00 am | RNS | Avacta Presents Phase 1a Data for Faridoxorubicin |
| 13th Oct 2025 7:00 am | RNS | Avacta to present data at EORTC-NCI-AACR |